# US 2022/0276246 A1 · Kit for predicting or diagnosing nonalcoholic fatty liver disease, and method for diagnosing nonalcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276246 A1
- Document ID: US20220276246A1
- Status: Published application
- Kind: A1
- Application number: 17/626,632
- Filed: 2020-07-30
- Published: 2022-09-01
- Earliest claimed: 2019-07-30
- Assignees: Kobiolabs, Inc.
- Applicants: KoBioLabs, Inc.
- Inventors: Gwang Pyo KO; Won KIM; Hyun Ju YOU; Giljae LEE
- Web page: https://patentgrep.com/patent/US20220276246A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 47/02: Inorganic compounds
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12N 1/20: Bacteria; Culture media therefor
- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- G01N 2333/26: Klebsiella (G)
- G01N 2333/36: from Actinomyces; from Streptomyces (G)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a kit for predicting or diagnosing the degree of risk of disease, a method for providing information for predicting or diagnosing the degree of risk of disease, a method for screening a therapeutic agent of disease, and a pharmaceutical composition for prevention or treatment of disease, for nonalcoholic fatty liver disease. Specifically, through the kit for predicting or diagnosing of the present invention, the degree of risk of nonalcoholic fatty liver disease can be effectively predicted or diagnosed, and in particular, the predictive value and significance of information provision in non-obese subjects are excellent. Therefore, by providing effective information on nonalcoholic fatty liver disease through this, it can be effectively used to prevent or treat the corresponding disease. In addition, the pharmaceutical composition for prevention or treatment of the present invention may be effectively used for treatment of nonalcoholic fatty liver disease.

## Claims

### Claim 1

A kit for predicting or diagnosing a degree of risk of nonalcoholic fatty liver disease comprising a detection means detecting one or more detection markers selected from the group consisting of
(a) one or more detection markers selected from the group consisting of microbial biomarkers of nonalcoholic fatty liver disease;
(b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid; and
(c) intestinal short chain fatty acid.

### Claim 2 (depends on 1)

The kit according to claim 1, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Rikenellaceae, Fusobacteriaceae, Ruminococcaceae, Lachnospiraceae, Actinomycetaceae, Desulfovibrioceae and Desulfovibrionaceae.

### Claim 3 (depends on 1)

The kit according to claim 1, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Citrobacter, Klebsiella, Veillonella, Megamonas, Fusobacterium, Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, Actinomyces and Desulfovibrio,
wherein the (b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid are one or more selected from the group consisting of total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, or
wherein the (c) intestinal short chain fatty acid is one or more selected from the group consisting of acetate, propionate and butyrate.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The kit according to claim 1, wherein the kit comprises one or more selected from combinations of (a) to (p) below:
(a) one or more detection means capable of detecting one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae and Ruminococcaceae, respectively;
(b) one or more detection means capable of detecting one or more selected from the group consisting of total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, respectively;
(c) one or more detection means capable of detecting one or more selected from the group consisting of short chain fatty acid, acetate, propionate and butyrate, respectively;
(d) one or more detection means capable of detecting one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae, Ruminococcaceae, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and propionate, respectively;
(e) one or more detection means capable of detecting one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, respectively;
(f) one or more detection means capable of detecting one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira and fecal propionate, respectively;
(g) one or more detection means capable of detecting one or more selected from the group consisting of Veillonella, Megamonas, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, respectively;
(h) one or more detection means capable of detecting one or more selected from the group consisting of Veillonella, Megamonas and fecal propionate, respectively,
(i) one or more detection means capable of detecting one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Ruminococcaceae, Citrobacter, Klebsiella, Veillonella, Megamonas, Ruminococcus, Faecalibacterium and Oscillospira, respectively;
(j) one or more detection means capable of detecting one or more selected from the group consisting of cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and metabolites thereof, respectively;
(k) one or more detection means capable of detecting one or more selected from the group consisting of intestinal short chain fatty acid and propionate, respectively,
(l) a detection means capable of detecting Enterobacteriaceae, Veillonellaceae, and Ruminococcaceae,
(m) a detection means capable of detecting Megamonas and Ruminococcus,
(n) a detection means capable of detecting cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, and propionate,
(o) combination of (l) and (n), or
(p) combination of (m) and (n).

### Claim at position 6

7-11. (canceled)

### Claim 12 (depends on 1)

The kit according to claim 1, wherein the nonalcoholic fatty liver disease is nonalcoholic fatty liver, nonalcoholic steatohepatitis, liver fibrosis or cirrhosis.

### Claim 13 (depends on 1)

The kit according to claim 1, wherein the nonalcoholic fatty liver disease is non-obese nonalcoholic fatty liver disease, or wherein the kit is for a non-obese patient.

### Claim 14 (depends on 1)

The kit according to claim 1, wherein the predicting the degree of risk is predicting the severity of fibrosis comprising F=0 to F=4.

### Claim 15

(canceled)

### Claim 16

A method for providing information for predicting or diagnosing a degree of risk of nonalcoholic fatty liver disease comprising detecting one or more detection markers selected from the group consisting of
(a) one or more detection markers selected from the group consisting of microbial biomarkers of nonalcoholic fatty liver disease;
(b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid; and
(c) intestinal short chain fatty acid.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Rikenellaceae, Fusobacteriaceae, Ruminococcaceae, Lachnospiraceae, Actinomycetaceae, Desulfovibrioceae and Desulfovibrionaceae.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Citrobacter, Klebsiella, Veillonella, Megamonas, Fusobacterium, Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, Actinomyces, and Desulfovibrio,
wherein the (b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid are one or more selected from the group consisting of total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, or
wherein the (c) intestinal short chain fatty acid is one or more selected from the group consisting of acetate, propionate and butyrate.

### Claim at position 14

19-20. (canceled)

### Claim 21 (depends on 16)

The method according to claim 16, wherein the method comprises one or more steps selected from combinations of (a) to (p) below:
(a) comparing abundances of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae and Ruminococcaceae measured in a subject, with a reference value of a healthy individual;
(b) comparing the contents in feces of one or more selected from the group consisting of total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid measured in a subject, with a reference value of a healthy individual;
(c) comparing the contents in feces of one or more selected from the group consisting of short chain fatty acid, acetate, propionate and butyrate measured in a subject, with a reference value of a healthy individual;
(d) comparing abundances or the contents in feces of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae, Ruminococcaceae, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and propionate measured in a subject, with a reference value of a healthy individual;
(e) comparing abundances or the contents in feces of one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid measured in a subject, with a reference value of a healthy individual;
(f) comparing abundances or the contents in feces of one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira and feces propionate measured in a subject, with a reference value of a healthy individual;
(g) comparing abundances or the contents in feces of one or more selected from the group consisting of Veillonella, Megamonas, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid measured in a subject, with a reference value of a healthy individual;
(h) comparing abundances or the contents in feces of one or more selected from the group consisting of Veillonella, Megamonas and feces propionate measured in a subject, with a reference value of a healthy individual;
(i) comparing abundances of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Ruminococcaceae, Citrobacter, Klebsiella, Veillonella, Megamonas, Ruminococcus, Faecalibacterium and Oscillospira measured in a subject, with a reference value of a healthy individual;
(j) comparing the contents in feces of one or more selected from the group consisting of cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and metabolites thereof measured in a subject, with a reference value of a healthy individual;
(k) comparing the contents in feces of one or more selected from the group consisting of intestinal short chain fatty acid and propionate measured in a subject, with a reference value of a healthy individual,
(l) comparing abundances of Enterobacteriaceae, Veillonellaceae, and Ruminococcaceae measured in a subject, with a reference value of a healthy individual;
(m) comparing abundances of Megamonas and Ruminococcus measured in a subject, with a reference value of a healthy individual;
(n) comparing the contents in feces of cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and propionate measured in a subject, with a reference value of a healthy individual;
(o) comprising (l) and (n); and
(p) comprising (m) and (n).

### Claim at position 16

22-25. (canceled)

### Claim 26 (depends on 16)

The method according to claim 16, wherein the nonalcoholic fatty liver disease is nonalcoholic fatty liver, nonalcoholic steatohepatitis, liver fibrosis or cirrhosis.

### Claim 27 (depends on 16)

The method according to claim 16, wherein the nonalcoholic fatty liver disease is non-obese nonalcoholic fatty liver disease, or
wherein the method is for a non-obese patient.

### Claim 28 (depends on 16)

The method according to claim 16, wherein the method further comprises treating the subject determined to have risk of nonalcoholic fatty liver disease.

### Claim 29

A method for screening a therapeutic agent for nonalcoholic fatty liver disease, comprising
(1) administering a test substance to an experimental animal having nonalcoholic fatty liver disease;
(2) measuring one or more of detection markers selected from the group consisting of (a) one or more detection markers selected from the group consisting of microbial biomarkers of nonalcoholic fatty liver disease; (b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid; and (c) one or more detection markers selected from the group consisting of intestinal short chain fatty acids, in an experimental animal untreated with the test substance and the experimental animal administered with the test substance; and
(3) comparing the measured results in a control group untreated with the test substance and the experimental animal administered with the test substance.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Rikenellaceae, Fusobacteriaceae, Ruminococcaceae, Lachnospiraceae, Actinomycetaceae, Desulfovibrioceae and Desulfovibrionaceae.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the (a) microbial biomarkers of nonalcoholic fatty liver disease are one or more selected from the group consisting of Citrobacter, Klebsiella, Veillonella, Megamonas, Fusobacterium, Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, Actinomyces, and Desulfovibrio,
wherein the (b) one or more detection markers selected from the group consisting of total bile acid and components of bile acid are total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid, and deoxycholic acid, or
wherein the (c) intestinal short chain fatty acid is one or more selected from the group consisting of acetate, propionate and butyrate.

### Claim at position 23

32-33. (canceled)

### Claim 34 (depends on 25)

The method for screening a therapeutic agent of nonalcoholic fatty liver according to claim 25, wherein the method comprises one or more steps selected from combinations of (a) to (p) below:
(a) comparing abundances of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae and Ruminococcaceae, measured before and after administration of a candidate substance of therapeutic agent;
(b) comparing the contents in feces of one or more selected from the group consisting of total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, measured before and after administration of a candidate substance of therapeutic agent;
(c) comparing the contents in feces of one or more selected from the group consisting of short chain fatty acid, acetate, propionate and butyrate, measured before and after administration of a candidate substance of therapeutic agent;
(d) comparing abundances or the contents in feces of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Lachnospiraceae, Ruminococcaceae, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and propionate, measured before and after administration of a candidate substance of therapeutic agent;
(e) comparing abundances or the contents in feces of one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, measured before and after administration of a candidate substance of therapeutic agent;
(f) comparing abundances or the contents in feces of one or more selected from the group consisting of Ruminococcus, Faecalibacterium, Oscillospira, Coprococcus, Lachnospira and feces propionate, measured before and after administration of a candidate substance of therapeutic agent;
(g) comparing abundances or the contents in feces of one or more selected from the group consisting of Veillonella, Megamonas, total bile acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid and deoxycholic acid, measured before and after administration of a candidate substance of therapeutic agent;
(h) comparing abundances or the contents in feces of one or more selected from the group consisting of Veillonella, Megamonas and feces propionate, measured before and after administration of a candidate substance of therapeutic agent;
(i) comparing abundances of one or more selected from the group consisting of Enterobacteriaceae, Veillonellaceae, Ruminococcaceae, Citrobacter, Klebsiella, Veillonella, Megamonas, Ruminococcus, Faecalibacterium and Oscillospira, measured before and after administration of a candidate substance of therapeutic agent;
(j) comparing the contents in feces of one or more selected from the group consisting of cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and metabolites thereof, measured before and after administration of a candidate substance of therapeutic agent;
(k) comparing the contents in feces of one or more selected from the group consisting of intestinal short chain fatty acids and propionate, measured before and after administration of a candidate substance of therapeutic agent;
(l) comparing abundances of Enterobacteriaceae, Veillonellaceae, and Ruminococcaceae, measured before and after administration of a candidate substance of therapeutic agent;
(m) comparing abundances of Megamonas and Ruminococcus, measured before and after administration of a candidate substance of therapeutic agent;
(n) comparing the contents in feces of cholic acid, chenodeoxycholic acid, ursodeoxycholic acid and propionate, measured before and after administration of a candidate substance of therapeutic agent;
(o) comprising the (l) and (n); and
(p) comprising the (m) and (n).

### Claim 35

(canceled)

### Claim 36 (depends on 29)

The method for screening a therapeutic agent for nonalcoholic fatty liver disease according to claim 29, wherein the nonalcoholic fatty liver disease is non-obese nonalcoholic fatty liver disease.

### Claim at position 27

37-42. (canceled)

### Claim 43 (depends on 16)

The method according to claim 16, wherein the method further comprises administering a therapeutic agent of nonalcoholic fatty to the subject determined to have risk of nonalcoholic fatty liver disease.
